Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma

MS Davids; G Von Keudell; CA Portell; JB Cohen; DC Fisher; F Foss; AW Roberts; JF Seymour; RA Humerickhouse; CS Tam

Journal article

Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma

MS Davids, G Von Keudell, CA Portell, JB Cohen, DC Fisher, F Foss, AW Roberts, JF Seymour, RA Humerickhouse, CS Tam

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2018

DOI: 10.1200/JCO.18.00359

University of Melbourne Researchers

Andrew Roberts Author

John Seymour Author

Constantine Tam Author

Grants

Funding Acknowledgements

Venetoclax is being developed in collaboration between AbbVie and Genentech-Roche. AbbVie, Genentech-Roche, and Janssen Pharmaceuticals provided financial support for the venetoclax clinical studies. AbbVie and Genentech-Roche were involved in the writing, review, and approval of this correspondence. Medical writing and support were provided by Ryan J. Bourgo, PhD, and Sharanya Ford, PhD, of AbbVie.